1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Celltrion, Inc.
  6. News
  7. Summary
    A068270   KR7068270008

CELLTRION, INC.

(A068270)
  Report
End-of-day quote Korea Stock Exchange  -  2022-08-04
197000.00 KRW   +4.23%
08/05S.Korean shares post third straight weekly gain
RE
08/05CELLTRION : 2Q 2022 Earnings Release_Celltrion Inc.
PU
07/26Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on May 18, 2022.
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Celltrion Eyes to Boost Market Share in Europe of Rheumatoid Arthritis Medication to 50%

06/06/2022 | 03:35am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
CELLTRION, INC. 4.23% 197000 End-of-day quote.-0.51%
KOSPI COMPOSITE INDEX 0.80% 2493.1 Real-time Quote.-16.24%
All news about CELLTRION, INC.
08/05S.Korean shares post third straight weekly gain
RE
08/05CELLTRION : 2Q 2022 Earnings Release_Celltrion Inc.
PU
07/26Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on May 18, 2022.
CI
07/26Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on May 18, 2022.
CI
07/22Celltrion, Inc.'s Equity Buyback announced on May 18, 2022, has closed with 500,000 sha..
CI
07/19Hikma and Celltrion sign exclusive licensing agreement for YuflymaTM for the Middle Eas..
AQ
06/26Celltrion Wins Sales Approval Recommendation For Its CT-P16 From European Medicines Age..
RE
06/06Celltrion Eyes to Boost Market Share in Europe of Rheumatoid Arthritis Medication to 50..
MT
05/18Celltrion, Inc. authorizes a Buyback Plan.
CI
05/17Celltrion, Inc. announces an Equity Buyback for 500,000 shares.
CI
More news
Analyst Recommendations on CELLTRION, INC.
More recommendations
Financials
Sales 2022 1 969 B 1,51 B 1,51 B
Net income 2022 618 B 0,47 B 0,47 B
Net cash 2022 673 B 0,52 B 0,52 B
P/E ratio 2022 47,1x
Yield 2022 0,17%
Capitalization 27 138 B 20 815 M 20 815 M
EV / Sales 2022 13,4x
EV / Sales 2023 10,7x
Nbr of Employees 2 034
Free-Float 75,0%
Chart CELLTRION, INC.
Duration : Period :
Celltrion, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELLTRION, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 197 000,00 KRW
Average target price 193 160,78 KRW
Spread / Average Target -1,95%
EPS Revisions
Managers and Directors
Wu-Sung Ki Chief Executive Officer & Director
Ho-Seop Lee Finance Director
Jung-Jin Seo Chairman
Sung-Han Lee Head-Legal & Compliance Support
Dong-Il Kim Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CELLTRION, INC.-0.51%20 815
MODERNA, INC.-26.44%73 092
IQVIA HOLDINGS INC.-16.94%43 781
LONZA GROUP AG-26.44%43 083
SEAGEN INC.13.72%32 426
ALNYLAM PHARMACEUTICALS, INC.28.89%26 235